title: Malignant potential of Barrett's esophagus: special reference to HDAC-1 and MTA-1 expression.
abstract: OBJECTIVE
  Barrett's esophagus is a major risk factor for esophageal adenocarcinoma. It is important to decide when and how to treat the patients with Barrett's esophagus (BE). It was reported that HDAC-1 (Histone Deacetylase-1) and MTA-1 (Metastasis-Associated Protein-1) were associated with initiation and progression of cancer. The aim of this study is to assess malignant potential of BE using the expression of HDAC-1 and MTA-1.
  
  
  METHODS
  Seven BE cases with pathological specialized columnar epithelium and CK7/20 in an immunohistochemically positive state were selected from resected specimens of 23 patients with gastro-esophageal junction cancer. The expression of HDAC-1 and MTA-1 protein was evaluated using an immunohistochemical method.
  
  
  RESULTS
  All seven cases with Barrett's esophagus were diagnosed as low grade dysplasia. Positive expression of HDAC-1 and MTA-1 was found in 0 out of 7 cases (0%) with normal esophageal epithelium, and 0 out of 7 cases (0%) with normal gastric epithelium. On the other hand, positive expression of both HDAC-1 and MTA-1 was found in 6 out of 7 (85.7%) cases with Barrett's epithelium and 7 out of 7 (100%) cases with gastro-esophageal-junction-cancer, respectively.
  
  
  CONCLUSIONS
  Positive expression of HDAC-1 and MTA-1 was found even in low grade dysplasia. Therefore, BE with HDAC-1 and MTA-1 expression is considered to be a precancerous lesion re quiring curative treatment.
authors.affiliation: Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Miyatani
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Kurita
authors.forename: Chie
authors.initials: C
authors.lastname: Mikami
authors.forename: Hideya
authors.initials: H
authors.lastname: Kashihara
authors.forename: Jun
authors.initials: J
authors.lastname: Higashijima
authors.forename: Kozo
authors.initials: K
authors.lastname: Yoshikawa
authors.forename: Masanori
authors.initials: M
authors.lastname: Nishioka
authors.forename: Hirohiko
authors.initials: H
authors.lastname: Sato
authors.forename: Tahashi
authors.initials: T
authors.lastname: Iwata
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Shimada
mesh_terms: D001471:Barrett Esophagus / Q000209:etiology* / Q000378:metabolism / Q000473:pathology; D004938:Esophageal Neoplasms / Q000150:complications*; D056284:Histone Deacetylase 1 / Q000032:analysis*; D006655:Histone Deacetylases / Q000032:analysis*; D006801:Humans; D007150:Immunohistochemistry; D053554:Keratin-20 / Q000032:analysis; D053552:Keratin-7 / Q000032:analysis; D012097:Repressor Proteins / Q000032:analysis*; D015534:Trans-Activators
chemical_list: D053554:Keratin-20; D053552:Keratin-7; C089320:MTA1 protein, human; D012097:Repressor Proteins; D015534:Trans-Activators; C110550:HDAC1 protein, human; D056284:Histone Deacetylase 1; D006655:Histone Deacetylases